{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:43:29Z","timestamp":1792118609315,"version":"4.4.0"},"reference-count":293,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.tube.2010.02.001","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T05:32:19Z","timestamp":1268803939000},"page":"94-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["Rifamycins \u2013 Obstacles and opportunities"],"prefix":"10.1016","volume":"90","author":[{"given":"Paul A.","family":"Aristoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Kirchhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.D.","family":"Hollis Showalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2010.02.001_bib1","unstructured":"World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO Report; 2008."},{"key":"10.1016\/j.tube.2010.02.001_bib2","first-page":"1907","article-title":"Rifampin, a general review","volume":"21","author":"Binda","year":"1971","journal-title":"Arzneim-Forsch"},{"key":"10.1016\/j.tube.2010.02.001_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1517\/13543776.17.6.617","article-title":"New anti-tuberculosis therapies","volume":"17","author":"Portero","year":"2007","journal-title":"Expert Opin Ther Patents"},{"key":"10.1016\/j.tube.2010.02.001_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2741\/1293","article-title":"The search for new sterilizing anti-tuberculosis drugs","volume":"9","author":"Mitchison","year":"2004","journal-title":"Front Biosci"},{"key":"10.1016\/j.tube.2010.02.001_bib5","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.2174\/1381612043383287","article-title":"In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infection","volume":"10","author":"Lounis","year":"2004","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.tube.2010.02.001_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/clinids\/9.3.519","article-title":"Rifabutin (Ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases","volume":"9","author":"O'Brien","year":"1987","journal-title":"Rev Infectious Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib7","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.2174\/138161206778743646","article-title":"Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities","volume":"12","author":"Tomioka","year":"2006","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.tube.2010.02.001_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/499950","article-title":"Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders","volume":"42","author":"Adachi","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/17425250902973695","article-title":"Rifaximin pharmacology and clinical implications","volume":"5","author":"Ojetti","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.tube.2010.02.001_bib10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003495-199856040-00008","article-title":"Rifapentine","volume":"56","author":"Jarvis","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.tube.2010.02.001_bib11","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1086\/508278","article-title":"Rifapentine for the treatment of pulmonary tuberculosis","volume":"43","author":"Munsiff","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ccm.2005.02.013","article-title":"New drugs for tuberculosis: current status and future prospects","volume":"26","author":"O'Brien","year":"2005","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.tube.2010.02.001_bib13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1345\/aph.18450","article-title":"Rifapentine: its role in the treatment of tuberculosis","volume":"33","author":"Temple","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.tube.2010.02.001_bib14","first-page":"951","article-title":"Rifamycin SV, a review","volume":"8","author":"Bergamini","year":"1965","journal-title":"Arzneim-Forsch"},{"key":"10.1016\/j.tube.2010.02.001_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6468(08)70351-5","article-title":"Some recently introduced drugs","volume":"7","author":"Launchbury","year":"1970","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1517\/13543784.15.6.603","article-title":"Development potential of rifalazil and other benzoxazinorifamycins","volume":"15","author":"Rothstein","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.tube.2010.02.001_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ardp.200700080","article-title":"Rifalazil and other benzoxazinorifamycins in the treatment of Chlamydia-bases persistent infections","volume":"340","author":"Rothstein","year":"2007","journal-title":"Arch Pharm Chem Life Sci"},{"key":"10.1016\/j.tube.2010.02.001_bib18","series-title":"Comprehensive medicinal chemistry II","first-page":"699","article-title":"Antimycobacterium agents","author":"Ma","year":"2007"},{"key":"10.1016\/j.tube.2010.02.001_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/157340607780620626","article-title":"In search of new cures for tuberculosis","volume":"3","author":"Protopopova","year":"2007","journal-title":"Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.drudis.2008.09.004","article-title":"New anti-tuberculosis drugs in clinical trials with novel mechanisms of action","volume":"13","author":"Rivers","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.tube.2010.02.001_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1753465808099522","article-title":"Managing TB in the 21st century: existing and novel drug therapies","volume":"2","author":"Guy","year":"2008","journal-title":"Therapeut Adv Respir Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib22","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1440-1843.2008.01342.x","article-title":"Development of new antituberculosis drugs: its relevance worldwide and in the Asia-Pacific region","volume":"13","author":"Tam","year":"2008","journal-title":"Respirology"},{"key":"10.1016\/j.tube.2010.02.001_bib23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1172\/JCI34614","article-title":"Confronting the scientific obstacles to global control of tuberculosis","volume":"118","author":"Young","year":"2008","journal-title":"J Clin Investig"},{"key":"10.1016\/j.tube.2010.02.001_bib24","first-page":"600","article-title":"Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents","volume":"8","author":"Chopra","year":"2007","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.tube.2010.02.001_bib25","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2174\/092986709787315559","article-title":"Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development","volume":"16","author":"Mariani","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib26","first-page":"146","article-title":"Rifomycin, a new antibiotic \u2013 preliminary report","volume":"14","author":"Sensi","year":"1959","journal-title":"Farmaco Ed Sci"},{"key":"10.1016\/j.tube.2010.02.001_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1021\/ar50050a003","article-title":"Antibiotics with ansa rings","volume":"5","author":"Rinehart","year":"1972","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.tube.2010.02.001_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BFb0048448","article-title":"Ansamycin \u2013 chemistry, biosynthesis and biological activity","volume":"72","author":"Wehrli","year":"1977","journal-title":"Top Curr Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/207417a0","article-title":"Effect of rifamycin on protein synthesis","volume":"207","author":"Calvori","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.tube.2010.02.001_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/cr030112j","article-title":"Rifamycin-mode of action, resistance, and biosynthesis","volume":"105","author":"Floss","year":"2005","journal-title":"Chem Rev"},{"key":"10.1016\/j.tube.2010.02.001_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0005-2787(67)90147-5","article-title":"The specific inhibition of the DNA-directed RNA synthesis by rifamycin","volume":"145","author":"Hartmann","year":"1967","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tube.2010.02.001_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0005-2787(68)90285-2","article-title":"Action of rifamycins on RNA polymerase","volume":"157","author":"Wehrli","year":"1968","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tube.2010.02.001_bib33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1128\/br.35.3.290-309.1971","article-title":"Actions of the rifamycins","volume":"35","author":"Wehrli","year":"1971","journal-title":"Bacteriol Rev"},{"key":"10.1016\/j.tube.2010.02.001_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0005-2787(68)90515-7","article-title":"The inhibition of bacterial RNA synthesis by the rifamycin antibiotics","volume":"166","author":"Wilhelm","year":"1968","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tube.2010.02.001_bib35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2741\/1289","article-title":"Mechanism of drug resistance in Mycobacterium tuberculosis","volume":"9","author":"Wade","year":"2004","journal-title":"Front Biosci"},{"key":"10.1016\/j.tube.2010.02.001_bib36","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: mechanisms of action and resistance","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1073\/pnas.61.2.667","article-title":"Interaction of rifamycin with bacterial RNA polymerase","volume":"61","author":"Wehrli","year":"1968","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.tube.2010.02.001_bib38","doi-asserted-by":"crossref","first-page":"8949","DOI":"10.1016\/S0021-9258(17)34269-2","article-title":"On the mechanism of rifampicin inhibition of RNA synthesis","volume":"253","author":"McClure","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.sbi.2009.10.010","article-title":"Structures of RNA polymerase-antibiotic complexes","volume":"19","author":"Ho","year":"2009","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.tube.2010.02.001_bib40","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.tube.2010.02.001_bib41","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1529\/biophysj.104.050187","article-title":"Distance-restrained docking of rifampicin and rifamycin SV to RNA polymerase using systematic FRET measurements: developing benchmarks of model quality and reliability","volume":"88","author":"Knight","year":"2005","journal-title":"Biophys J"},{"key":"10.1016\/j.tube.2010.02.001_bib42","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.42.7.1853","article-title":"Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis","volume":"42","author":"Williams","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4161\/cc.5.4.2466","article-title":"Is it easy to stop RNA polymerase?","volume":"5","author":"Artsimovitch","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.tube.2010.02.001_bib44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cell.2005.07.014","article-title":"Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins","volume":"122","author":"Artsimovitch","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.tube.2010.02.001_bib45","doi-asserted-by":"crossref","first-page":"14820","DOI":"10.1073\/pnas.0802822105","article-title":"Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center","volume":"105","author":"Feklistov","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2010.02.001_bib46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/07391102.2008.10507185","article-title":"Homology modeling of wild-type, D516V, and H526L Mycobacterium tuberculosis RNA polymerase and their molecular docking study with inhibitor","volume":"25","author":"Josa","year":"2007","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.tube.2010.02.001_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tibs.2004.02.005","article-title":"New inhibitors targeting bacterial RNA polymerase","volume":"29","author":"Darst","year":"2004","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.tube.2010.02.001_bib48","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1016\/j.bmc.2006.05.035","article-title":"A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus","volume":"14","author":"Arhin","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cell.2008.09.033","article-title":"The RNA polymerase \u201cswitch region\u201d is a target for inhibitors.[see comment]","volume":"135","author":"Mukhopadhyay","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.tube.2010.02.001_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1128\/AAC.43.1.181","article-title":"ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene","volume":"43","author":"Quan","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib51","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1073\/pnas.0711939105","article-title":"Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr","volume":"105","author":"Baysarowich","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2010.02.001_bib52","first-page":"139","article-title":"Rifamycins as inhibitors of RNA and DNA polymerases","volume":"2","author":"Gurgo","year":"1977","journal-title":"Pharmac Ther"},{"key":"10.1016\/j.tube.2010.02.001_bib53","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/978-3-642-68487-6_13","article-title":"Rifamycins","author":"Gurgo","year":"1982","journal-title":"Chemother Viral Infect"},{"key":"10.1016\/j.tube.2010.02.001_bib54","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/jm00220a009","article-title":"3-N-Substituted aminomethyl derivatives of rifamycin SV. A convenient method of synthesis, cyclization of certain derivatives, and anticellular and antiviral activities of several derivatives","volume":"20","author":"McCarthy","year":"1977","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0005-2787(76)90227-6","article-title":"Interaction of rifamycins with mammalian nucleic acid polymerizing enzymes","volume":"454","author":"Sethi","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tube.2010.02.001_bib56","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7164\/antibiotics.28.580","article-title":"Effect of the rifamycin dimers on the activities of nucleic acid polymerases from various sources. Relation between lipophily and toxicity","volume":"28","author":"Talpaert-Borle","year":"1975","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib57","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/anie.196806931","article-title":"Antibiotics as inhibitors of nucleic acid and protein synthesis","volume":"7","author":"Hartmann","year":"1968","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.tube.2010.02.001_bib58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0005-2787(69)90516-4","article-title":"The rifamycins-relation of chemical structure and action on RNA polymerase","volume":"182","author":"Wehrli","year":"1969","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tube.2010.02.001_bib59","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0005-2787(68)90086-5","article-title":"Inhibition of DNA-dependent RNA polymerase reaction of Escherichia coli by an antimicrobial antibiotic, streptovaricin","volume":"157","author":"Mizuno","year":"1968","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tube.2010.02.001_bib60","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/bi00702a004","article-title":"Relative biological activities of individual streptovaricins and streptovaricin acetates","volume":"13","author":"Rinehart","year":"1974","journal-title":"Biochemistry"},{"key":"10.1016\/j.tube.2010.02.001_bib61","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7164\/antibiotics.29.201","article-title":"Identification and preparation of damavaricins, biologically active presursors of streptovaricins","volume":"29","author":"Rinehart","year":"1976","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7164\/antibiotics.29.147","article-title":"Chemical modification of streptovaricin C.I. 19-O-Substituted damavaricin C","volume":"29","author":"Sasaki","year":"1976","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib63","first-page":"327","article-title":"X-ray crystal structure and activity of rifamycinol, a semi-synthetic derivative of the antibacterial antibiotic rifamycin S showing a dimeric \u03c0\u2013\u03c0 complex in the crystal","author":"Cellai","year":"1987","journal-title":"J Chem Res"},{"key":"10.1016\/j.tube.2010.02.001_bib64","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0026-895X(25)14618-X","article-title":"Structure\u2013activity relationships in the ansamycins. Molecular structure and activity of 3-carbomethoxy rifamyin S","volume":"21","author":"Brufani","year":"1982","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.tube.2010.02.001_bib65","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1039\/p29820001633","article-title":"A study on the structures of 3-methoxycarbonyrifamycins by x-ray crystallography and 1H nuclear magnetic resonance spectroscopy","author":"Cellai","year":"1982","journal-title":"J Chem Soc Perkin Trans II"},{"key":"10.1016\/j.tube.2010.02.001_bib66","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1021\/ja00854a057","article-title":"Electronegative groups at C-3 of rifamycin S enhance its activity toward DNA-dependent RNA polymerase","volume":"97","author":"Dampier","year":"1975","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.tube.2010.02.001_bib67","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1021\/ja00438a055","article-title":"Substituent effects on the solution conformation of rifamycin S","volume":"98","author":"Dampier","year":"1976","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.tube.2010.02.001_bib68","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1021\/jm00146a021","article-title":"Correlation of structure and activity in ansamycins: structure, conformation, and interactions of antibiotic rifamycin S","volume":"28","author":"Arora","year":"1985","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0223-5234(89)90103-7","article-title":"Mechanism of inhibition of DNA-dependent RNA polymerase of Escherichia coli by rifamycins","volume":"24","author":"Cellai","year":"1989","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0026-895X(25)14257-0","article-title":"Correlation of structure and activity in ansamycins. Molecular structure of sodium rifamycin SV","volume":"23","author":"Arora","year":"1983","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.tube.2010.02.001_bib71","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hlca.19930760406","article-title":"Hydrogenation of the ansa-chain of rifamycins. X-ray crystal structure of (16S)-16,17,18,19-tetrahydrorifamycin S","volume":"76","author":"Bartolucci","year":"1993","journal-title":"Helv Chim Acta"},{"key":"10.1016\/j.tube.2010.02.001_bib72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0022-2836(74)90094-1","article-title":"Rifamycins: an insight into biological activity based on structural investigations","volume":"87","author":"Brufani","year":"1974","journal-title":"J Mol Biol"},{"key":"10.1016\/j.tube.2010.02.001_bib73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1008070316079","article-title":"Conformational variety for the ansa chain of rifamycins: comparison of observed crystal structures and molecular dynamics simulations","volume":"13","author":"Bacchi","year":"1999","journal-title":"J Comput-Aided Mol Des"},{"key":"10.1016\/j.tube.2010.02.001_bib74","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1021\/jm970791o","article-title":"Comprehensive study on structure\u2013activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O","volume":"41","author":"Bacchi","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib75","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1128\/AAC.39.7.1489","article-title":"Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648","volume":"39","author":"Fujii","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0005-2787(76)90040-X","article-title":"Purification and properties of DNA-dependent RNA polymerase from Mycobacterium tuberculosis H37Rv","volume":"432","author":"Harshey","year":"1976","journal-title":"Biochim Biophys Acta (BBA) \u2013 Nucl Acids Protein Synth"},{"key":"10.1016\/j.tube.2010.02.001_bib77","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1128\/AAC.49.4.1587-1590.2005","article-title":"Different rifampin sensitivities of Escherichia coli and Mycobacterium tuberculosis RNA polymerases are not explained by the difference in the {beta}-subunit rifampin regions I and II","volume":"49","author":"Zenkin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1351\/pac197541010015","article-title":"Recent progress in the chemistry and biochemistry of rifamycins","volume":"41","author":"Sensi","year":"1975","journal-title":"Pure Appl Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib79","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","article-title":"History of the development of rifampin","volume":"5","author":"Sensi","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib80","first-page":"576","article-title":"Streptovaricin. Discovery and biological activity","volume":"75","author":"Siminoff","year":"1957","journal-title":"Am Rev Tubercul Pulm Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib81","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1021\/jm00220a012","article-title":"Synthesis and antimicrobial activity of some derivatives of tolypomycinone. Relationship between structure and activity in ansamycins","volume":"20","author":"Bellomo","year":"1977","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib82","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.7164\/antibiotics.31.1195","article-title":"A new tolypomycin-Y derivative: in vitro and in vivo antimicrobial activity","volume":"31","author":"Stanzani","year":"1978","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib83","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/jm00335a005","article-title":"Rifamycins. XXXV. Amides and hydrazides of rifamycin B","volume":"7","author":"Sensi","year":"1964","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib84","first-page":"800","article-title":"In vitro bacteriological studies on rifamycin B diethyamide (rifamide)","volume":"15","author":"Pallanza","year":"1965","journal-title":"Arzneim-Forsch"},{"key":"10.1016\/j.tube.2010.02.001_bib85","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1021\/jm00143a010","article-title":"Synthesis and antibacterial activity of some esters, amides, and hydrazides of 3-carboxyrifamycin S: relationship between structure and activity in ansamycins","volume":"24","author":"Bellomo","year":"1981","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib86","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7164\/antibiotics.34.1033","article-title":"New rifamycins modified at positions 3 and 4: synthesis, structure and biological evaluation","volume":"34","author":"Marsili","year":"1981","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib87","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/jm00308a042","article-title":"The influence of the carboxy group upon the antibacterial activity of rifamycins","volume":"11","author":"Maggi","year":"1968","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib88","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.7164\/antibiotics.34.1026","article-title":"Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative","volume":"34","author":"Arioli","year":"1981","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib89","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jac\/46.4.571","article-title":"Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex","volume":"46","author":"Bemer-Melchior","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib90","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/jm00250a005","article-title":"Oximes of 3-formylrifamycin SV. Synthesis, antibacterial activity, and other biological properties","volume":"17","author":"Cricchio","year":"1974","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib91","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.7164\/antibiotics.37.1209","article-title":"3-Aminomethylazinomethylrifamycins. A new class of rifamycins, endowed with remarkable antibacterial activity","volume":"37","author":"Marsili","year":"1984","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib92","doi-asserted-by":"crossref","first-page":"779","DOI":"10.7164\/antibiotics.38.779","article-title":"Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250","volume":"38","author":"Della Bruna","year":"1985","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib93","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.7164\/antibiotics.35.1621","article-title":"Unusual rearrangement of 3-hydrazino-rifamycins leading to the enlargement of the \u201cnatural\u201d ansa bridge","volume":"35","author":"Marsili","year":"1982","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib94","first-page":"619","article-title":"The antibacterial activity of a new 3-azinomethylrifamycin","volume":"43","author":"Strippoli","year":"1988","journal-title":"Farmaco, Ed Sci"},{"key":"10.1016\/j.tube.2010.02.001_bib95","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0041-3879(90)90005-S","article-title":"In vitro activities against mycobacteria of two long-acting rifamycins FCE 22807 and CGP40\/469A (SPA-S-565)","volume":"71","author":"Dickinson","year":"1990","journal-title":"Tubercle"},{"key":"10.1016\/j.tube.2010.02.001_bib96","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1128\/AAC.39.10.2320","article-title":"Antimycobacterial activity of a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl)rifamycin SV (T9)","volume":"39","author":"Reddy","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib97","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1348-0421.2006.tb03836.x","article-title":"Antimicrobial activities of cinnamyl rifamycin derivatives, T-9 and T-11, against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) with special reference to the activities against intracellular MAC","volume":"50","author":"Sato","year":"2006","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.tube.2010.02.001_bib98","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1002\/ejoc.200600184","article-title":"Study of the reaction of 3-formylrifamycin SV with gaseous ammonia and acetone","author":"Bujnowski","year":"2006","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib99","unstructured":"Marsili L, Pasqualucci C, Rossetti V. USA Patent US 4217278 19800812; 1980."},{"key":"10.1016\/j.tube.2010.02.001_bib100","unstructured":"Kanebo Ltd. Japan Patent JP 56045482 19810425; 1981."},{"key":"10.1016\/j.tube.2010.02.001_bib101","unstructured":"Taguchi M, Aikawa N, Tsukamoto G, Utsumi I. Japan Patent JP 54106500 19790821; 1979."},{"key":"10.1016\/j.tube.2010.02.001_bib102","unstructured":"Kump W. Germany Patent DD 239795 A5 19861008; 1986."},{"key":"10.1016\/j.tube.2010.02.001_bib103","unstructured":"Kump W. Patent US 4918066 A 19900417; 1990."},{"key":"10.1016\/j.tube.2010.02.001_bib104","unstructured":"Ovchinnikov DV, Polukeev VA. Russia Patent RU 2245337 C2 20050127. 2005."},{"key":"10.1016\/j.tube.2010.02.001_bib105","unstructured":"Schuyeuemann G, Kuehne RMO, Nedeyalkova ZA, Andrew PW, Shafi J, Sharpe JA, et-al. Patent WO 2003084965 A1 20031016; 2003."},{"key":"10.1016\/j.tube.2010.02.001_bib106","unstructured":"Dimov DI, Angelova NT, Grozdanov GA, Penev PN, Khaladzhova ST, Nubcgevam DT, et-al. Patent BG 104585 A 20020131; 2002."},{"key":"10.1016\/j.tube.2010.02.001_bib107","unstructured":"Wu J, Li J, Huang J. China Patent CN 1654467 A 20050817; 2005."},{"key":"10.1016\/j.tube.2010.02.001_bib108","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1248\/cpb.31.144","article-title":"Studies on quantitative structure\u2013activity relationships. V. QSAR investigations of rifamycin B amides and hydrazides by utilization of the substituent entropy constants","volume":"31","author":"Kawaki","year":"1983","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.tube.2010.02.001_bib109","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1021\/jm00238a002","article-title":"Structure\u2013activity correlations among rifamycin B amides and hydrazides","volume":"18","author":"Quinn","year":"1975","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3998\/ark.5550190.0008.e15","article-title":"Topological modeling of antimycobacterial activity of 3-formyl rifamycin SV derivatives","volume":"14","author":"Deeb","year":"2007","journal-title":"Arkivoc"},{"key":"10.1016\/j.tube.2010.02.001_bib111","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/1521-3838(200111)20:4<298::AID-QSAR298>3.0.CO;2-Z","article-title":"QSAR modeling of antimycobacterial activity and activity against other bacteria of 3-formyl rifamycin SV derivatives","volume":"20","author":"Dimov","year":"2001","journal-title":"Quant Struct-Act Relat"},{"key":"10.1016\/j.tube.2010.02.001_bib112","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1128\/AAC.00343-07","article-title":"In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm","volume":"51","author":"Villain-Guillot","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib113","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0026-895X(25)11449-1","article-title":"A study of structure\u2013activity relationships in 4-deoxypyrido[1\u2032,2\u2032-1,2]imidazo[5,4-c]rifamycin SV derivatives by electron spectroscopy for chemical analysis and 1H NMR","volume":"27","author":"Cellai","year":"1984","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.tube.2010.02.001_bib114","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1021\/jm00167a029","article-title":"Synthesis and biological activity of some derivatives of rifamycin P","volume":"33","author":"Cavalleri","year":"1990","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib115","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.7164\/antibiotics.36.1495","article-title":"Synthesis and antibacterial activity of 3-amidino- and of 4-aminoimidazolo[4,5-c]rifamycin derivatives","volume":"36","author":"Marsili","year":"1983","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib116","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.7164\/antibiotics.33.1193","article-title":"Biological activity of a new class of rifamycins: spiro-piperidyl-rifamycins","volume":"33","author":"Sanfilippo","year":"1980","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib117","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1164\/ajrccm\/145.1.212","article-title":"Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages","volume":"145","author":"Dhillon","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib118","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0924-8579(97)00016-2","article-title":"Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis","volume":"8","author":"Dhople","year":"1997","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2010.02.001_bib119","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/42.5.621","article-title":"Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis","volume":"42","author":"Yang","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1472-9792(08)70022-2","article-title":"Rifabutin","volume":"88","author":"Global Alliance for TB Drug Development","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2010.02.001_bib121","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.bmcl.2006.08.090","article-title":"New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis","volume":"16","author":"Barleunga","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tube.2010.02.001_bib122","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mrc.1545","article-title":"NMR spectroscopic analysis of new spiro-piperidylrifamycins","volume":"43","author":"Rubio","year":"2005","journal-title":"Magn Reson Chem2005"},{"key":"10.1016\/j.tube.2010.02.001_bib123","first-page":"654","article-title":"NMR spectroscopic analysis of new spiro-piperidylrifamycins","volume":"44","author":"Rubio","year":"2006","journal-title":"Magn Reson Chem (Erratum)"},{"key":"10.1016\/j.tube.2010.02.001_bib124","unstructured":"Barleunga Mur J, Aznar Gomez F, Cabal Naves MP, Garcia Delgado AB, Valdes Gomez C. Patent WO 2006\/027397 A1; 2006."},{"key":"10.1016\/j.tube.2010.02.001_bib125","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.bmcl.2006.12.026","article-title":"Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins","volume":"17","author":"Kim","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tube.2010.02.001_bib126","first-page":"68","article-title":"Rifamycins. XLII. Rifazine, a new phenazine derivative of rifamycins","volume":"21","author":"Gallo","year":"1966","journal-title":"Farmaco, Ed Sci"},{"key":"10.1016\/j.tube.2010.02.001_bib127","first-page":"699","article-title":"Chemical modifications and biological properties of rifamycins","volume":"6","author":"Sensi","year":"1966","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib128","first-page":"352","article-title":"New derivatives of rifamycin antibiotics","volume":"6","author":"Bickel","year":"1966","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib129","first-page":"359","article-title":"Chemotherapeutic activity of new derivatives of rifamycin","volume":"6","author":"Kradolfer","year":"1966","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib130","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1248\/cpb.40.2707","article-title":"Synthesis and biological activity of 5\u2032-aminobenzoxazinorifamycin derivatives","volume":"40","author":"Yamane","year":"1992","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.tube.2010.02.001_bib131","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1248\/cpb.41.148","article-title":"Synthesis and biological activity of 3\u2032-hydroxy-5\u2032aminobenzoxazinorifamycin derivatives","volume":"41","author":"Yamane","year":"1993","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.tube.2010.02.001_bib132","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1128\/AAC.35.3.542","article-title":"In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins","volume":"35","author":"Saito","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib133","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.39.2.440","article-title":"In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli","volume":"39","author":"Luna-Herrera","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib134","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/AAC.40.2.426","article-title":"In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis","volume":"40","author":"Yamamoto","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib135","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.40.11.2655","article-title":"Comparative antimycobacterial activities of rifampin, rifapentine and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations","volume":"40","author":"Moghazeh","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib136","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1128\/AAC.50.5.1908-1909.2006","article-title":"Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes","volume":"50","author":"Mullin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib137","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.47.3.1135-1136.2003","article-title":"In vitro activities of rifamycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae","volume":"47","author":"Roblin","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib138","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ja.2006.43","article-title":"Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro","volume":"59","author":"Osburne","year":"2006","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib139","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ja.2006.11","article-title":"In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus","volume":"59","author":"Osburne","year":"2006","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib140","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ja.2007.72","article-title":"In vitro activity of novel rifamycins against gram-positive clinical isolates","volume":"60","author":"Murphy","year":"2007","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib141","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/AAC.50.3.827-834.2006","article-title":"In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus","volume":"50","author":"Murphy","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib142","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/jac\/dkn133","article-title":"In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus","volume":"62","author":"Tsuji","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib143","unstructured":"van Duzer JH, Michaelis AF, Geiss WB, Stafford DG, Raker J. Patent 2005\/0043298 A1; 2005."},{"key":"10.1016\/j.tube.2010.02.001_bib144","unstructured":"van Duzer JH, Michaelis AF, Geiss WB, Stafford DG, Raker J, Yu XY, et-al. Patent US 2005\/0197333 A1; 2005."},{"key":"10.1016\/j.tube.2010.02.001_bib145","unstructured":"van Duzer JH, Michaelis AF, Geiss WB, Stafford DG, Yu XY, Siedlecki JM, et-al. USA Patent US 2005\/0137189 A1; 2005."},{"key":"10.1016\/j.tube.2010.02.001_bib146","unstructured":"van Duzer JH, Siedlecki JM, Yu XY. USA Patent US 2007\/0105849 A1; 2007."},{"key":"10.1016\/j.tube.2010.02.001_bib147","unstructured":"Kano F, Yamane T, Kondo H, Yamashita K, Hosoe K, Watanabe K. Japan Patent JP 63333987 A 19880929; 1988."},{"key":"10.1016\/j.tube.2010.02.001_bib148","unstructured":"Kano F, Yamane T, Yamashita K, Hosoe K, Watanabe K. Japan Patent JP 63122689 A 19880526; 1988."},{"key":"10.1016\/j.tube.2010.02.001_bib149","unstructured":"Taguchi M, Aikawa K, Tsukamoto G, Kawashima H, Utsumi I. Japan Patent JP 54073799 19790613; 1979."},{"key":"10.1016\/j.tube.2010.02.001_bib150","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0040-4020(03)00184-4","article-title":"Rifamycin antibiotics-new compounds and synthetic methods. Part 1: Study of the reaction of 3-formylrifamycin SV with primary alkylamines or ammonia","volume":"59","author":"Bujnowski","year":"2003","journal-title":"Tetrahedron"},{"key":"10.1016\/j.tube.2010.02.001_bib151","unstructured":"Kanebo Ltd. Japan Patent JP 56016487 19810217; 1981."},{"key":"10.1016\/j.tube.2010.02.001_bib152","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1016\/j.bmcl.2007.08.048","article-title":"Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins","volume":"17","author":"Li","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tube.2010.02.001_bib153","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1021\/jm00311a004","article-title":"Acetyl migration in rifampicin","volume":"11","author":"Maggi","year":"1968","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib154","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jac\/46.4.565","article-title":"Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG","volume":"46","author":"Rastogi","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib155","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.7164\/antibiotics.38.1799","article-title":"Identification of urinary metabolites of rifamycin LM 427 in man","volume":"38","author":"Vigevani","year":"1985","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib156","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.7164\/antibiotics.40.1733","article-title":"CGP 4832, a new semisynthetic rifamycin derivative highly active against some Gram-negative bacteria","volume":"55","author":"Wehrli","year":"1987","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib157","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0969-2126(01)00631-1","article-title":"Active transport of an antibiotic rifamycin derivative by the outer-membrane protein FhuA","volume":"9","author":"Ferguson","year":"2001","journal-title":"Structure"},{"key":"10.1016\/j.tube.2010.02.001_bib158","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1099\/00221287-133-12-3505","article-title":"Highly efficient uptake of a rifamycin derivative via the FhuA-TonB-dependent uptake route in Escherichia coli","volume":"133","author":"Pugsley","year":"1987","journal-title":"J\u00a0General Microbiol"},{"key":"10.1016\/j.tube.2010.02.001_bib159","unstructured":"Combrink K, Harran S, Denton D, Ma Z. USA Patent US 20055256096 A1 20051117; 2005."},{"key":"10.1016\/j.tube.2010.02.001_bib160","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bmcl.2006.10.016","article-title":"New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases","volume":"17","author":"Combrink","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tube.2010.02.001_bib161","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1128\/AAC.01649-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib162","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/AAC.01651-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib163","unstructured":"Ding CZ, Kim IH, Wang J, Ma Z, Jin Y, Combrink KD, Lu G, Lynch AS. Patent WO 2008008480 A2 20080117; 2008."},{"key":"10.1016\/j.tube.2010.02.001_bib164","unstructured":"Ding CZ, Jin Y, Combrink K, Kim IH. Patent WO 2009064792 A1 20090522; 2009."},{"key":"10.1016\/j.tube.2010.02.001_bib165","first-page":"588","article-title":"III. In vivo studies in the tuberculous mouse","volume":"75","author":"Rhuland","year":"1957","journal-title":"Am Rev Tubercul Pulm Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib166","first-page":"216","article-title":"Antituberculous action of rifamycin SV, in vitro and in vivo studies","volume":"15","author":"Tsukamura","year":"1962","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib167","first-page":"802","article-title":"Rifamycin B diethylamide (rifamide): activity in experimental infection, absorption and elimination in man","volume":"7","author":"Furesz","year":"1965","journal-title":"Arzneim-Forsch"},{"key":"10.1016\/j.tube.2010.02.001_bib168","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1164\/ajrccm.161.5.9904090","article-title":"Antituberculosis activity of once-weekly rifapentine-containing regimens in mice","volume":"161","author":"Daniel","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib169","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.43.10.2356","article-title":"Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice","volume":"43","author":"Lenaerts","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib170","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1128\/AAC.45.12.3482-3486.2001","article-title":"Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice","volume":"45","author":"Lounis","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib171","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1128\/AAC.39.9.2073","article-title":"Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages","volume":"39","author":"Mor","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib172","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1128\/AAC.38.10.2346","article-title":"Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis","volume":"38","author":"Jabes","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib173","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/AAC.38.5.1118","article-title":"In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives","volume":"38","author":"Fujii","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib174","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1128\/AAC.42.11.3047","article-title":"Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model","volume":"42","author":"Brooks","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib175","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1128\/AAC.38.10.2245","article-title":"Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib176","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1128\/AAC.40.12.2809","article-title":"Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis","volume":"40","author":"Kelly","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib177","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/AAC.40.2.298","article-title":"Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model","volume":"40","author":"Klemens","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib178","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1128\/AAC.44.11.3167-3168.2000","article-title":"Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model","volume":"44","author":"Lenaerts","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib179","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1128\/AAC.44.6.1458-1462.2000","article-title":"Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice","volume":"44","author":"Shoen","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib180","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1128\/AAC.01087-05","article-title":"Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection","volume":"50","author":"Rothstein","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib181","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1128\/AAC.01567-07","article-title":"Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection","volume":"52","author":"Campbell","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib182","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ja.2006.107","article-title":"Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model","volume":"59","author":"Lee","year":"2006","journal-title":"J Antibiot"},{"key":"10.1016\/j.tube.2010.02.001_bib183","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.00120-07","article-title":"Efficacy of a novel rifamycin derivative, ABI-0043 against Staphylococcus aureus in an experimental model of foreign-body infection","volume":"51","author":"Trampuz","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib184","unstructured":"Renick PJ, Morris TW, Nguyen PM, Pulse ME, Weiss WJ. Efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in rodent models of bacterial infection. Poster presented at the 47th ICAAC, Chicago, Illinois 2007; Abstract F1-2105."},{"key":"10.1016\/j.tube.2010.02.001_bib185","unstructured":"Grosset JHE. Short-course treatment of active TB with FDA approved agents: prediction from animal models. In: 47th ICAAC. Chicago, Illinois, 2007."},{"key":"10.1016\/j.tube.2010.02.001_bib186","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1164\/rccm.200602-280OC","article-title":"Potent twice-weekly rifapentine-containing regimens in murine tuberculosis","volume":"174","author":"Rosenthal","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib187","first-page":"1931","article-title":"Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model","volume":"4","author":"Rosenthal","year":"2007","journal-title":"PLoS"},{"key":"10.1016\/j.tube.2010.02.001_bib188","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.tube.2010.02.001_bib189","first-page":"367","article-title":"Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis","volume":"123","author":"Dickinson","year":"1981","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib190","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib191","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib192","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","article-title":"Clinical pharmacokinetics of rifampicin","volume":"3","author":"Acocella","year":"1978","journal-title":"Clin Pharmacokin"},{"key":"10.1016\/j.tube.2010.02.001_bib193","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1093\/clinids\/5.Supplement_3.S428","article-title":"Pharmacokinetics and metabolism of rifampin in humans","volume":"5","author":"Acocella","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib194","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/004982597239994","article-title":"Rifampin and rifabutin and their metabolism by human liver esterases","volume":"27","author":"Jamis-Dow","year":"1997","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tube.2010.02.001_bib195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1472-9792(08)70024-6","article-title":"Rifampin","volume":"88","author":"Global Alliance for TB Drug Development","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2010.02.001_bib196","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1128\/AAC.45.12.3631-3634.2001","article-title":"Postantibiotic effects of antituberculosis agents alone and in combination","volume":"45","author":"Chan","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib197","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1472-9792(08)70025-8","article-title":"Rifapentine","volume":"88","author":"Global Alliance for TB Drug Development","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2010.02.001_bib198","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1128\/AAC.43.5.1230","article-title":"Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a Phase I study","volume":"43","author":"Keung","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib199","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1128\/AAC.48.1.340-343.2004","article-title":"In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis","volume":"48","author":"Chan","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1164\/rccm.200411-1557OC","article-title":"The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis","volume":"172","author":"Sirgel","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib201","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","article-title":"Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy","volume":"169","author":"Weiner","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib202","first-page":"60","article-title":"Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species","volume":"50","author":"Bruzzese","year":"2000","journal-title":"Arzneim-Forsch\/Drug Res"},{"key":"10.1016\/j.tube.2010.02.001_bib203","first-page":"137","article-title":"Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin","volume":"18","author":"Kelkar","year":"1998","journal-title":"Int J Clin Pharm Res"},{"key":"10.1016\/j.tube.2010.02.001_bib204","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000007176","article-title":"Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin","volume":"45","author":"Potkar","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.tube.2010.02.001_bib205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000238165","article-title":"Pharmacokinetics of L\/105, a new rifamycin, in rats and dogs, after oral administration","volume":"29","author":"Venturini","year":"1983","journal-title":"Chemotherapy"},{"key":"10.1016\/j.tube.2010.02.001_bib206","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-3565(25)21290-3","article-title":"In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats","volume":"279","author":"Koudriakova","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.tube.2010.02.001_bib207","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1128\/AAC.33.8.1237","article-title":"Pharmacokinetics of rifabutin","volume":"33","author":"Skinner","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib208","first-page":"963","article-title":"Isolation and identification of major urinary metabolites of rifabutin in rats and humans","volume":"25","author":"Utkin","year":"1997","journal-title":"Drug Metab Dispo"},{"key":"10.1016\/j.tube.2010.02.001_bib209","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/00498258909042314","article-title":"Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers","volume":"19","author":"Cocchiara","year":"1989","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tube.2010.02.001_bib210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jac\/36.2.355","article-title":"In vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli","volume":"36","author":"Luna-Herrera","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib211","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib212","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000220506","article-title":"Distribution, excretion and toxicity of rifazine, a new semisynthetic rifamycin","volume":"12","author":"Schiatti","year":"1967","journal-title":"Chemotherapia"},{"key":"10.1016\/j.tube.2010.02.001_bib213","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1128\/AAC.40.12.2749","article-title":"Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs","volume":"40","author":"Hosoe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib214","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1472-9792(08)70023-4","article-title":"Rifalazil","volume":"88","author":"Global Alliance for TB Drug Development","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2010.02.001_bib215","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0091270007300745","article-title":"Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.tube.2010.02.001_bib216","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3109\/00498259609046749","article-title":"In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform","volume":"26","author":"Mae","year":"1996","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tube.2010.02.001_bib217","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/004982599237967","article-title":"Isolation and identification of major metabolites of rifalazil in mouse and human","volume":"29","author":"Mae","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tube.2010.02.001_bib218","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/004982500406408","article-title":"Identification of enzymes responsible for rifalazil metabolism in human liver microsomes","volume":"30","author":"Mae","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tube.2010.02.001_bib219","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin, clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.tube.2010.02.001_bib220","first-page":"1001","article-title":"Rifampicin lowers moxifloxacin level in TB patients","volume":"45","author":"Douglas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib221","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-2797(97)00071-9","article-title":"Primary human hepatocytes as a tool for the evaluation of structure\u2013activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin","volume":"107","author":"Li","year":"1997","journal-title":"Chemico-Biol Interact"},{"key":"10.1016\/j.tube.2010.02.001_bib222","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0009-9236(99)70138-4","article-title":"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive","volume":"65","author":"Barditch-Crovo","year":"1999","journal-title":"Clin Pharmaco Ther"},{"key":"10.1016\/j.tube.2010.02.001_bib223","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jac\/37.6.1111","article-title":"Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver","volume":"37","author":"Oesch","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib224","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF00615223","article-title":"Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects","volume":"34","author":"Perucca","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.tube.2010.02.001_bib225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1043-6618(05)80021-0","article-title":"Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs","volume":"32","author":"Benedetti","year":"1995","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.tube.2010.02.001_bib226","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1086\/313771","article-title":"Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis","volume":"30","author":"Narita","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib227","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/004982598239173","article-title":"Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog","volume":"28","author":"Mae","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tube.2010.02.001_bib228","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tube.2010.02.001_bib229","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.bbrc.2005.04.071","article-title":"Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type 1","volume":"331","author":"Sporstol","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.tube.2010.02.001_bib230","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/jhep.2000.8539","article-title":"Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2","volume":"32","author":"Fattinger","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.tube.2010.02.001_bib231","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interaction of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.tube.2010.02.001_bib232","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cbi.2004.08.008","article-title":"Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia","volume":"150","author":"Campbell","year":"2004","journal-title":"Chemico-Biol Interact"},{"key":"10.1016\/j.tube.2010.02.001_bib233","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.102.043026","article-title":"Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation","volume":"304","author":"Tirona","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.tube.2010.02.001_bib234","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2008.01.042","article-title":"Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3","volume":"584","author":"Gui","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.tube.2010.02.001_bib235","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1124\/dmd.106.010033","article-title":"Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes","volume":"34","author":"Jigorel","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.tube.2010.02.001_bib236","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clpt.2006.07.006","article-title":"Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins","volume":"80","author":"Oswald","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.tube.2010.02.001_bib237","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/bdd.268","article-title":"CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit","volume":"22","author":"Weber","year":"2001","journal-title":"Biopharmaceut Drug Dispos"},{"key":"10.1016\/j.tube.2010.02.001_bib238","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/00498250500296231","article-title":"In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice and humanized liver","volume":"35","author":"Katoh","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tube.2010.02.001_bib239","article-title":"Tackling drug-interaction issues early on","volume":"28","author":"Lipp","year":"2008","journal-title":"Genet Eng Biotechnol News"},{"key":"10.1016\/j.tube.2010.02.001_bib240","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.tube.2010.02.001_bib241","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11095-005-8812-5","article-title":"Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome P450 Induction potential of drugs in vivo in humans","volume":"23","author":"Persson","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.tube.2010.02.001_bib242","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1208\/aapsj070102","article-title":"A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line","volume":"7","author":"Trubetskoy","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.tube.2010.02.001_bib243","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1124\/dmd.104.001594","article-title":"High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line","volume":"33","author":"Yueh","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.tube.2010.02.001_bib244","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-4827(73)90551-X","article-title":"A direct effect of some rifamycin derivatives on the morphology of mammalian mitochondria","volume":"77","author":"Follett","year":"1973","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.tube.2010.02.001_bib245","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0003-9861(74)90091-5","article-title":"In vitro inhibition of Saccharomyces cerevisiae RNA polymerase by rifamycin derivatives (Rifamycins and yeast RNA polymerase)","volume":"164","author":"Di Mauro","year":"1974","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.tube.2010.02.001_bib246","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0167-4889(97)90008-2","article-title":"Effect of metal ion catalyzed oxidation of rifamycin SV on cell viability and metabolic performance of isolated rat hepatocytes","volume":"1092","author":"Guillermo","year":"1991","journal-title":"Biochim Biophy Acta"},{"key":"10.1016\/j.tube.2010.02.001_bib247","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0003-9861(92)90455-6","article-title":"Stimulation of microsomal production of reactive oxygen intermediates by rifamycin SV: effect of ferric complexes and comparisons between NADPH and NADH","volume":"298","author":"Kukielka","year":"1992","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.tube.2010.02.001_bib248","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0041-008X(66)90109-8","article-title":"Pharmacology and toxicology of rifamide","volume":"8","author":"Dezulian","year":"1966","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.tube.2010.02.001_bib249","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/3.2.115","article-title":"Adverse reactions to rifampicin in antituberculosis regimens","volume":"3","author":"Girling","year":"1977","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib250","first-page":"45","article-title":"Adverse reactions to rifampicin","volume":"57","author":"Girling","year":"1979","journal-title":"Bull World Health Org"},{"key":"10.1016\/j.tube.2010.02.001_bib251","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"Grosset","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib252","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.tube.2010.02.001_bib253","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0041-3879(70)90029-2","article-title":"Jaundice associated with rifampicin","volume":"51","author":"Hollins","year":"1970","journal-title":"Tubercle"},{"issue":"7855","key":"10.1016\/j.tube.2010.02.001_bib254","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0140-6736(74)92381-2","article-title":"Rifampicin hepatitis. A clinical and histological study","volume":"1","author":"Scheuer","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2010.02.001_bib255","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long-term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tube.2010.02.001_bib256","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials","volume":"26","author":"Khurana","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.tube.2010.02.001_bib257","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00005792-199911000-00001","article-title":"Hypersensitivity reactions to rifampin: pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions","volume":"78","author":"Martinez","year":"1999","journal-title":"Medicine"},{"key":"10.1016\/j.tube.2010.02.001_bib258","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/bmj.2.5916.415","article-title":"Sensitivity to rifampicin: incidence, mechanism, and prevention","volume":"2","author":"Pujet","year":"1974","journal-title":"Brit Med J"},{"key":"10.1016\/j.tube.2010.02.001_bib259","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/bmj.2.5861.282","article-title":"Massive haemolysis caused by rifampicin","volume":"2","author":"Lakshminarayan","year":"1973","journal-title":"Brit Med J"},{"key":"10.1016\/j.tube.2010.02.001_bib260","first-page":"743","article-title":"Acute hemolysis and renal failure following discontinuous use of rifampin","volume":"25","author":"Levine","year":"1991","journal-title":"DICP, Ann Pharmacother"},{"key":"10.1016\/j.tube.2010.02.001_bib261","first-page":"68","article-title":"Mild intravasal haemolysis associated with flu-syndrome during intermittent rifampicin treatment","volume":"63","author":"Mattson","year":"1982","journal-title":"Eur J Respir Dis"},{"issue":"8251","key":"10.1016\/j.tube.2010.02.001_bib262","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(81)91123-5","article-title":"Failure to stimulate antibodies in man after 7 days high-dose treatment with rifampicin","volume":"2","author":"Brumfett","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2010.02.001_bib263","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2222.1973.tb01342.x","article-title":"Relationship between rifampicin-dependent antibody scores, serum rifampicin concentrations and symptoms in patients with adverse reactions to intermittent rifampicin treatment","volume":"3","author":"O'Mahoney","year":"1973","journal-title":"Clin Allergy"},{"key":"10.1016\/j.tube.2010.02.001_bib264","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bmj.3.5770.343","article-title":"Potentially serious side effects of high-dose twice-weekly rifampicin","volume":"3","author":"Poole","year":"1971","journal-title":"Brit Med J"},{"key":"10.1016\/j.tube.2010.02.001_bib265","first-page":"125","article-title":"Correlation between the presence of rifampicin-dependent antibodies and clinical data","volume":"Suppl. 84","author":"Worlledge","year":"1973","journal-title":"Scand J Resp Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib266","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000091839","article-title":"Immediate hypersensitivity to rifampicin in 3 patients: diagnostic procedures and induction of clinical tolerance","volume":"140","author":"Buergin","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.tube.2010.02.001_bib267","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/08923979209009234","article-title":"Antimicrobial agents induce monocytes to release IL-1?, IL-6, and TNF, and induce lymphocytes to release IL-4 and TNF?","volume":"14","author":"Tufano","year":"1992","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.tube.2010.02.001_bib268","first-page":"357","article-title":"Immunomodulating activity of rifampicin","volume":"16","author":"Ziglam","year":"2004","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib269","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0024-3205(98)00360-9","article-title":"Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen","volume":"63","author":"Giuliani","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.tube.2010.02.001_bib270","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1128\/AAC.42.3.550","article-title":"Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes","volume":"42","author":"Tentori","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib271","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/AAC.50.1.396-398.2006","article-title":"Rifampin augments cytokine-induced nitric oxide production in human alveolar epithelial cells","volume":"50","author":"Yuhas","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib272","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.tube.2007.08.002","article-title":"Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis","volume":"87","author":"McIlleron","year":"2007","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2010.02.001_bib273","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","author":"Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib274","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1164\/rccm.200201-047OC","article-title":"A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment","volume":"165","author":"Bock","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib275","first-page":"3","article-title":"Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures","volume":"6","author":"Tam","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib276","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0962-8479(94)90079-5","article-title":"Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin","volume":"75","author":"Gonzalez-Montaner","year":"1994","journal-title":"Tubercle Lung Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib277","first-page":"1043","article-title":"Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study","volume":"3","author":"Matteelli","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib278","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"Winthrop KobotATSMDS. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib279","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/320512","article-title":"Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease","volume":"32","author":"Griffith","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib280","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/ajrccm.160.3.9811086","article-title":"Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease","volume":"160","author":"Tanaka","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib281","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1164\/ajrccm.153.6.8665032","article-title":"Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients","volume":"153","author":"Wallace","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.02.001_bib282","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199608083350602","article-title":"A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin","volume":"335","author":"Shafran","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2010.02.001_bib283","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/clinids\/21.3.594","article-title":"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease","volume":"21","author":"Griffith","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib284","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/clinids\/23.6.1321","article-title":"Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease","volume":"23","author":"Griffith","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.02.001_bib285","unstructured":"Rose LM, Porubek DJ, Montgomery AB. USA Patent US 6566354 B1; 2003."},{"key":"10.1016\/j.tube.2010.02.001_bib286","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1128\/AAC.45.7.1972-1976.2001","article-title":"Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis","volume":"45","author":"Dietze","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib287","unstructured":"Rose LM, Porubek DJ, Montgomery AB. USA Patent Application US 6566354 B1; 2003."},{"key":"10.1016\/j.tube.2010.02.001_bib288","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2174\/092986707781368496","article-title":"Novel agents in the management of Mycobacterium tuberculosis disease","volume":"14","author":"Barry","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.tube.2010.02.001_bib289","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/AAC.41.2.357","article-title":"Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice","volume":"41","author":"Tomioka","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib290","first-page":"141","article-title":"The sensitization models of rabbits to rifampicin and to two kinds of rifampicin-protein conjugates and the detection of rifampicin specific IgG in these models","volume":"3","author":"Li","year":"1994","journal-title":"J Chin Pharm Sci"},{"key":"10.1016\/j.tube.2010.02.001_bib291","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1128\/JB.187.8.2783-2792.2005","article-title":"Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics","volume":"187","author":"Xu","year":"2005","journal-title":"J Bacteriol"},{"key":"10.1016\/j.tube.2010.02.001_bib292","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1128\/AAC.39.10.2295","article-title":"In vitro and in vivo activities of the benoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis","volume":"39","author":"Hirata","year":"1995","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2010.02.001_bib293","unstructured":"Fernandes D, Sirokman K, Hazlett C, Gwathmey J, Van Duzer J, Brown K, et\u00a0al. Rifalazil and derivative compounds exhibit very potent in vivo activity against Staphylococcus aureus in a mouse septicemia model system. In: 43rd Interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, 2003. p. B-317."}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979210000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979210000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:38:49Z","timestamp":1761467929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979210000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":293,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1472979210000181"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2010.02.001","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifamycins \u2013 Obstacles and opportunities","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2010.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}